04.28.14
Avion Pharmaceuticals, Atlanta, GA, a specialty pharmaceutical company, has entered into a business partnership with Utah-based Albion Laboratories. The collaboration will focus on the licensing of unique, patented API ingredients and future product development for Avion’s women’s health portfolio.
Albion’s focus is natural mineral delivery systems, as well as developing intellectual property across several areas, including pharmaceutical-grade mineral nutrition and new mineral molecule forms for custom application. The alliance with Albion will positively align with Avion’s new product initiatives in prenatal and post-natal health. In addition, the partnership will further enforce Avion's focus on researching women’s health needs and developing products for women of all ages and life stages.
“Avion is relentless in the pursuit of innovation that will deliver improvements in products that support optimized lifestyles for patients,” said Mike Sullivan, president of Avion Pharmaceuticals. “This relationship with Albion will allow for continued development and commercialization of products that fill important gaps in nutrition.”
Avion CEO Mark Pugh added, “Albion’s expertise in mineral delivery systems and nutrition, married with Avion’s strong association with the Ob/Gyn community, bodes positively for a bright future that supports ongoing advances and additions to our existing portfolio.”
Albion’s focus is natural mineral delivery systems, as well as developing intellectual property across several areas, including pharmaceutical-grade mineral nutrition and new mineral molecule forms for custom application. The alliance with Albion will positively align with Avion’s new product initiatives in prenatal and post-natal health. In addition, the partnership will further enforce Avion's focus on researching women’s health needs and developing products for women of all ages and life stages.
“Avion is relentless in the pursuit of innovation that will deliver improvements in products that support optimized lifestyles for patients,” said Mike Sullivan, president of Avion Pharmaceuticals. “This relationship with Albion will allow for continued development and commercialization of products that fill important gaps in nutrition.”
Avion CEO Mark Pugh added, “Albion’s expertise in mineral delivery systems and nutrition, married with Avion’s strong association with the Ob/Gyn community, bodes positively for a bright future that supports ongoing advances and additions to our existing portfolio.”
